1. Home
  2. LABT vs NEXR Comparison

LABT vs NEXR Comparison

Compare LABT & NEXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$0.20

Market Cap

670.6K

Sector

Health Care

ML Signal

N/A

Logo Nexera Technologies Ltd Ordinary Shares

NEXR

Nexera Technologies Ltd Ordinary Shares

N/A

Current Price

$0.24

Market Cap

615.5K

ML Signal

N/A

Company Overview

Basic Information
Metric
LABT
NEXR
Founded
2006
2021
Country
United States
Israel
Employees
N/A
38
Industry
Biotechnology: Pharmaceutical Preparations
Other Specialty Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
670.6K
615.5K
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
LABT
NEXR
Price
$0.20
$0.24
Analyst Decision
Analyst Count
0
0
Target Price
★ $7.50
N/A
AVG Volume (30 Days)
607.7K
★ 6.9M
Earning Date
11-18-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.23
52 Week High
$6.85
$5.28

Technical Indicators

Market Signals
Indicator
LABT
NEXR
Relative Strength Index (RSI) 16.87 20.42
Support Level N/A $0.23
Resistance Level $2.13 $1.72
Average True Range (ATR) 0.06 0.11
MACD 0.01 -0.03
Stochastic Oscillator 1.52 1.11

Price Performance

Historical Comparison
LABT
NEXR

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

About NEXR Nexera Technologies Ltd Ordinary Shares

Nexera Technologies Ltd focuses on homeland security technologies, artificial intelligence-driven solutions, and detection systems through its subsidiaries and strategic collaborations. The company collaborates with technology partners to distribute and promote new systems such as 3D imaging and electromagnetic threat detection tools, autonomous security technologies, and multi-layered security ecosystems for critical infrastructure and high-traffic venues.

Share on Social Networks: